Acute myelomonocytic leukemia after treatment with chronic oral etoposide: are MLL and LTG9 genes targets for etoposide?
A patient with secondary acute myelomonocytic leukemia after treatment with chronic oral etoposide (VP-16) for lung cancer is reported. The leukemic cells showed a t(9;11)(p22;q23) translocation. Southern blot analysis revealed the rearrangement of the MLL (ALL-1/HRX) gene at 11q23. Reverse transcriptase-polymerase chain reaction (RT-PCR) revealed a chimeric mRNA between the MLL gene at 11q23 and LTG9 (MLLT3/AF-9) gene at 9p22. The patient was successfully treated with a VP-16 based regimen. This case is instructive in the understanding of the leukemogenesis of VP-16-related leukemias.
Goto
H
H
Second Department of Medicine, Kyoto Prefectural University of Medicine, Japan.
Shimazaki
C
C
Tatsumi
T
T
Yamagata
N
N
Inaba
T
T
Fujita
N
N
Moriguchi
T
T
Yamamoto
K
K
Seto
M
M
Ueda
R
R
D000284:Administration, Oral; D000368:Aged; D001483:Base Sequence; D018288:Carcinoma, Small Cell / Q000188:drug therapy; D002880:Chromosomes, Human, Pair 11; D002899:Chromosomes, Human, Pair 9; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects*; D005796:Genes / Q000187:drug effects*; D006801:Humans; D015479:Leukemia, Myelomonocytic, Acute / Q000139:chemically induced* / Q000235:genetics; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D008969:Molecular Sequence Data; D016609:Neoplasms, Second Primary / Q000139:chemically induced* / Q000235:genetics; D016133:Polymerase Chain Reaction; D014178:Translocation, Genetic
D005047:Etoposide